Price T Rowe Associates Inc Repligen Corp Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,568,316 shares of RGEN stock, worth $532 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
3,568,316
Previous 4,010,255
11.02%
Holding current value
$532 Million
Previous $721 Million
8.98%
% of portfolio
0.08%
Previous 0.1%
Shares
14 transactions
Others Institutions Holding RGEN
# of Institutions
522Shares Held
53.2MCall Options Held
1.05MPut Options Held
228K-
Black Rock Inc. New York, NY7.77MShares$1.16 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$760 Million0.02% of portfolio
-
State Street Corp Boston, MA1.76MShares$262 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C31.46MShares$218 Million0.31% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.43MShares$214 Million0.77% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.27B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....